Recent Updates
Recently added Catalysts
SRPT Positive Sentiment

Sarepta Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Key Takeaway: Sarepta Therapeutics, Inc. has announced its participation in investor conferences scheduled for June 2026. Senior management will present at the Goldman Sachs conference, which will be available via live webcast on the company's investor relations website. The presentation will also be archived for 90 days for future viewing.
Price reaction · baseline $17.61 (2026-06-01 close) · hit pre-market · clean, no other SRPT news in the window
day 0 close
-7.7%
day 1
-7.8%
day 3 · peak
-10.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sarepta is a leader in precision genetic medicine for rare diseases.
  • The company is actively engaging with investors through conferences.
  • Sarepta is building a robust portfolio across multiple disease areas.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
16.8%
average across 4 past catalysts
Lead asset
Eteplirsen
Phase 3 · Muscular Dystrophy, Duchenne

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June:
The presentation for the Goldman Sachs conference will be webcast live under the investor relations section of Sarepta’s website athttps://investorrelations.sarepta.com/events-presentationsand will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Frequently Asked Questions

When will Sarepta participate in investor conferences?

Sarepta Therapeutics will participate in investor conferences in June 2026.

Where can I watch the Goldman Sachs presentation?

The Goldman Sachs presentation will be webcast live on Sarepta's investor relations website.

How long will the presentation be available for viewing?

The presentation will be archived on the website for 90 days after the live event.

What is Sarepta's focus in genetic medicine?

Sarepta focuses on precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy.

Last updated: Jun 2, 2026